FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4353015296> ?p ?o ?g. }

• W4353015296 endingPage "741" @default.
• W4353015296 startingPage "740" @default.
• W4353015296 abstract "Movement DisordersEarly View HOT TOPICS Target-Specific Strategies to Modify the Course of Parkinson's: Is Iron Chelation Safe? Tiago A. Mestre MD, PhD, Corresponding Author Tiago A. Mestre MD, PhD [email protected] orcid.org/0000-0002-6973-7479 Parkinson's Disease and Movement Disorders Clinic, Division of Neurology, Department of Medicine, The Ottawa Hospital Research Institute/University of Ottawa Brain and Research Institute, Ottawa, Ontario, Canada Program in Neuroscience, Ottawa Hospital Research Institute, University of Ottawa Brain and Research Institute, Ottawa, Ontario, Canada Correspondence to: Dr. Tiago A. Mestre, Parkinson's Disease and Movement Disorders Clinic, Division of Neurology, Department of Medicine, The Ottawa Hospital, Ottawa, ON, Canada; E-mail: [email protected]Search for more papers by this authorMichael G. Schlossmacher MD, FRCPC, Michael G. Schlossmacher MD, FRCPC Parkinson's Disease and Movement Disorders Clinic, Division of Neurology, Department of Medicine, The Ottawa Hospital Research Institute/University of Ottawa Brain and Research Institute, Ottawa, Ontario, Canada Program in Neuroscience, Ottawa Hospital Research Institute, University of Ottawa Brain and Research Institute, Ottawa, Ontario, CanadaSearch for more papers by this author Tiago A. Mestre MD, PhD, Corresponding Author Tiago A. Mestre MD, PhD [email protected] orcid.org/0000-0002-6973-7479 Parkinson's Disease and Movement Disorders Clinic, Division of Neurology, Department of Medicine, The Ottawa Hospital Research Institute/University of Ottawa Brain and Research Institute, Ottawa, Ontario, Canada Program in Neuroscience, Ottawa Hospital Research Institute, University of Ottawa Brain and Research Institute, Ottawa, Ontario, Canada Correspondence to: Dr. Tiago A. Mestre, Parkinson's Disease and Movement Disorders Clinic, Division of Neurology, Department of Medicine, The Ottawa Hospital, Ottawa, ON, Canada; E-mail: [email protected]Search for more papers by this authorMichael G. Schlossmacher MD, FRCPC, Michael G. Schlossmacher MD, FRCPC Parkinson's Disease and Movement Disorders Clinic, Division of Neurology, Department of Medicine, The Ottawa Hospital Research Institute/University of Ottawa Brain and Research Institute, Ottawa, Ontario, Canada Program in Neuroscience, Ottawa Hospital Research Institute, University of Ottawa Brain and Research Institute, Ottawa, Ontario, CanadaSearch for more papers by this author First published: 21 March 2023 https://doi.org/10.1002/mds.29382 Relevant conflicts of interest/financial disclosures: Nothing to report. Funding agency: None. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. References 1Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L. The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol 2014; 13: 1045– 1060. 2Guiney SJ, Adlard PA, Bush AI, Finkelstein DI, Ayton S. Ferroptosis and cell death mechanisms in Parkinson's disease. Neurochem Int 2017; 104: 34– 48. 3Devos D et al. Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxid Redox Signal 2014; 21: 195– 210. 4Martin-Bastida A et al. Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease. Sci Rep 2017; 7: 1398. 5Devos D et al. Trial of Deferiprone in Parkinson's disease. N Engl J Med 2022; 387: 2045– 2055. 6Carballo-Carbajal I et al. Brain tyrosinase overexpression implicates age-dependent neuromelanin production in Parkinson's disease pathogenesis. Nat Commun 2019; 10: 973. Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation" @default.
• W4353015296 created "2023-03-23" @default.
• W4353015296 creator A5006896886 @default.
• W4353015296 creator A5067113888 @default.
• W4353015296 date "2023-03-21" @default.
• W4353015296 modified "2023-10-02" @default.
• W4353015296 title "Target‐Specific Strategies to Modify the Course of Parkinson's: Is Iron Chelation Safe?" @default.
• W4353015296 cites W2004628001 @default.
• W4353015296 cites W2112867510 @default.
• W4353015296 cites W2568082326 @default.
• W4353015296 cites W2609085690 @default.
• W4353015296 cites W2919982464 @default.
• W4353015296 cites W4311024711 @default.
• W4353015296 doi "https://doi.org/10.1002/mds.29382" @default.
• W4353015296 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36945748" @default.
• W4353015296 hasPublicationYear "2023" @default.
• W4353015296 type Work @default.
• W4353015296 citedByCount "0" @default.
• W4353015296 crossrefType "journal-article" @default.
• W4353015296 hasAuthorship W4353015296A5006896886 @default.
• W4353015296 hasAuthorship W4353015296A5067113888 @default.
• W4353015296 hasConcept C118552586 @default.
• W4353015296 hasConcept C126322002 @default.
• W4353015296 hasConcept C15744967 @default.
• W4353015296 hasConcept C161191863 @default.
• W4353015296 hasConcept C16568411 @default.
• W4353015296 hasConcept C169760540 @default.
• W4353015296 hasConcept C2778261627 @default.
• W4353015296 hasConcept C2779134260 @default.
• W4353015296 hasConcept C2779734285 @default.
• W4353015296 hasConcept C2991797542 @default.
• W4353015296 hasConcept C2993059035 @default.
• W4353015296 hasConcept C41008148 @default.
• W4353015296 hasConcept C512399662 @default.
• W4353015296 hasConcept C71924100 @default.
• W4353015296 hasConceptScore W4353015296C118552586 @default.
• W4353015296 hasConceptScore W4353015296C126322002 @default.
• W4353015296 hasConceptScore W4353015296C15744967 @default.
• W4353015296 hasConceptScore W4353015296C161191863 @default.
• W4353015296 hasConceptScore W4353015296C16568411 @default.
• W4353015296 hasConceptScore W4353015296C169760540 @default.
• W4353015296 hasConceptScore W4353015296C2778261627 @default.
• W4353015296 hasConceptScore W4353015296C2779134260 @default.
• W4353015296 hasConceptScore W4353015296C2779734285 @default.
• W4353015296 hasConceptScore W4353015296C2991797542 @default.
• W4353015296 hasConceptScore W4353015296C2993059035 @default.
• W4353015296 hasConceptScore W4353015296C41008148 @default.
• W4353015296 hasConceptScore W4353015296C512399662 @default.
• W4353015296 hasConceptScore W4353015296C71924100 @default.
• W4353015296 hasIssue "5" @default.
• W4353015296 hasLocation W43530152961 @default.
• W4353015296 hasLocation W43530152962 @default.
• W4353015296 hasOpenAccess W4353015296 @default.
• W4353015296 hasPrimaryLocation W43530152961 @default.
• W4353015296 hasRelatedWork W1966405986 @default.
• W4353015296 hasRelatedWork W2015065340 @default.
• W4353015296 hasRelatedWork W2018204675 @default.
• W4353015296 hasRelatedWork W2324226912 @default.
• W4353015296 hasRelatedWork W2559511909 @default.
• W4353015296 hasRelatedWork W2735157241 @default.
• W4353015296 hasRelatedWork W2743024085 @default.
• W4353015296 hasRelatedWork W2886374853 @default.
• W4353015296 hasRelatedWork W3164750928 @default.
• W4353015296 hasRelatedWork W4300167003 @default.
• W4353015296 hasVolume "38" @default.
• W4353015296 isParatext "false" @default.
• W4353015296 isRetracted "false" @default.
• W4353015296 workType "article" @default.